Skip to main content
. 2020 Feb 19;21(4):1387. doi: 10.3390/ijms21041387

Figure 5.

Figure 5

Doxorubicin and paclitaxel co-treated with WYE-354 decreased the survival rates of ABCB1-medited MDR cell lines. IC50 values of (A,D) doxorubicin, (B,E) paclitaxel and (C,F) cisplatin in drug-selected and ABCB1-transfected cell lines, respectively. Data were independently obtained from three experiments, shown as mean ± SD. * indicates p < 0.05 vs control.